Lupin gets USFDA nod for generic drugs to treat HIV infection

The tentative approval granted by the US Food and Drug Administration is for the abbreviated new drug application of Dolutegravir and Rilpivirine tablets of strength 50 mg/25 mg

FPJ Web DeskUpdated: Monday, January 16, 2023, 02:18 PM IST
article-image
Lupin gets USFDA nod for generic drugs to treat HIV infection | Image: Lupin (Representative)

Pharmaceutical firm Lupin announced that it has received tentative approval from the US health regulator to market its generic version of Dolutegravir and Rilpivirine tablets used in treatment of HIV infection, in an exchange filing.

The tentative approval granted by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) of Dolutegravir and Rilpivirine tablets of strength 50 mg/25 mg, Lupin said in the filing.

The Dolutegravir and Rilpivirine tablets, 50 mg/25 mg had estimated annual sales of USD 666 million in the US, the company said citing IQVIA MAT September 2022 data.

(If you have a story in and around Mumbai, you have our ears, be a citizen journalist and send us your story here. )

(To receive our E-paper on WhatsApp daily, please click here.  To receive it on Telegram, please click here. We permit sharing of the paper's PDF on WhatsApp and other social media platforms.)

RECENT STORIES

Indian traders accuse Samsung of anti-competitive practices, write to CCI

Indian traders accuse Samsung of anti-competitive practices, write to CCI

India's CAG calls AI game changer for public audit

India's CAG calls AI game changer for public audit

Tata, MG dragged back as EV sales drop by 10% in India

Tata, MG dragged back as EV sales drop by 10% in India

GVK Vice Chairman denies Rahul Gandhi's claims about pressure to sell Mumbai airport to Adani

GVK Vice Chairman denies Rahul Gandhi's claims about pressure to sell Mumbai airport to Adani

Axis Bank allots 2,80,256 shares as stock options for employees

Axis Bank allots 2,80,256 shares as stock options for employees